Reviewing Marker Therapeutics Inc. (MRKR)’s and Intec Pharma Ltd. (NASDAQ:NTEC)’s results – The Moveefy

Administrator Uncategorized 0

This is therefore a comparing of the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation in Marker Therapeutics Inc. (NASDAQ:MRKR) and Intec Pharma Ltd. (NASDAQ:NTEC). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Marker Therapeutics Inc. N/A 10585.84 15.08M -1.28 0.00
Intec Pharma Ltd. N/A 0.00 43.54M -1.40 0.00

Table 1 demonstrates Marker Therapeutics Inc. and Intec Pharma Ltd.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 represents Marker Therapeutics Inc. (NASDAQ:MRKR) and Intec Pharma Ltd. (NASDAQ:NTEC)’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Marker Therapeutics Inc. 0.00% -662.2% -295.8%
Intec Pharma Ltd. 0.00% 0% 0%

Insider & Institutional Ownership

Roughly 43.5% of Marker Therapeutics Inc. shares are held by institutional investors while 39.64% of Intec Pharma Ltd. are owned by institutional investors. Marker Therapeutics Inc.’s share held by insiders are 22.8%. Competitively, Intec Pharma Ltd. has 11.81% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Marker Therapeutics Inc. -3.11% 17.96% -10.86% -12.11% 96.23% 12.43%
Intec Pharma Ltd. -5.95% 4.85% 37.69% 116.32% 34.75% 9.02%

For the past year Marker Therapeutics Inc.’s stock price has bigger growth than Intec Pharma Ltd.


Marker Therapeutics Inc. beats Intec Pharma Ltd. on 5 of the 7 factors.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.


« »